Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review
Authors
Keywords
-
Journal
ESMO Open
Volume 6, Issue 5, Pages 100244
Publisher
Elsevier BV
Online
2021-09-01
DOI
10.1016/j.esmoop.2021.100244
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: first clinical experience
- (2021) Florian Eichhorn et al. LUNG CANCER
- Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study
- (2021) S. Hashemi et al. LUNG CANCER
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- (2021) Alexander M. Menzies et al. NATURE MEDICINE
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- (2021) Tina Cascone et al. NATURE MEDICINE
- FP03.02 Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)
- (2021) M.H. Hong et al. Journal of Thoracic Oncology
- PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
- (2021) J. Lee et al. Journal of Thoracic Oncology
- Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
- (2021) Nasser K Altorki et al. LANCET ONCOLOGY
- Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment
- (2021) Annikka Weissferdt et al. LUNG CANCER
- Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma
- (2021) Dijian Shen et al. Journal of Thoracic Disease
- Phase II trial of toripalimab plus chemotherapy as neoadjuvant treatment in resectable stage III non-small cell lung cancer (NeoTPD01 Study).
- (2021) Zerui Zhao et al. JOURNAL OF CLINICAL ONCOLOGY
- SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial
- (2021) Sacha I. Rothschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
- (2021) Jonathan Spicer et al. JOURNAL OF CLINICAL ONCOLOGY
- Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy
- (2020) Annikka Weissferdt et al. Clinical Lung Cancer
- IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY
- (2020) William D. Travis et al. Journal of Thoracic Oncology
- Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
- (2020) Shugeng Gao et al. Journal of Thoracic Oncology
- Current panorama and challenges for neoadjuvant cancer immunotherapy
- (2020) Jose Carlos BENITEZ et al. CLINICAL CANCER RESEARCH
- Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
- (2020) Catherine A Shu et al. LANCET ONCOLOGY
- 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
- (2020) B. Besse et al. ANNALS OF ONCOLOGY
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
- (2020) Arafat Tfayli et al. Cancer Medicine
- Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
- (2020) Joshua E Reuss et al. Journal for ImmunoTherapy of Cancer
- 62MO A randomised, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in locally advanced NSCLC
- (2020) J. Lei et al. ANNALS OF ONCOLOGY
- Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials
- (2019) Alberto Carretero-González et al. Oncotarget
- Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer
- (2018) Chi-Fu Jeffrey Yang et al. ANNALS OF THORACIC SURGERY
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma
- (2018) Yang Qu et al. Journal of Thoracic Oncology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- (2016) Peter Goldstraw et al. Journal of Thoracic Oncology
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
- (2014) LANCET
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
- (2014) Matthew D Hellmann et al. LANCET ONCOLOGY
- The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
- (2013) L. C. Villaruz et al. CLINICAL CANCER RESEARCH
- Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer
- (2011) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
- (2010) Enriqueta Felip et al. JOURNAL OF CLINICAL ONCOLOGY
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started